Click Holdings Limited (NASDAQ:CLIK – Get Free Report) fell 2.7% during mid-day trading on Monday . The company traded as low as $1.41 and last traded at $1.44. 325,145 shares changed hands during trading, a decline of 93% from the average session volume of 4,478,592 shares. The stock had previously closed at $1.48.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Click in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Get Our Latest Stock Report on Click
Click Stock Performance
Click (NASDAQ:CLIK – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million for the quarter.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Click stock. Renaissance Technologies LLC purchased a new stake in Click Holdings Limited (NASDAQ:CLIK – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click as of its most recent filing with the Securities and Exchange Commission (SEC).
About Click
Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.
Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.
Further Reading
- Five stocks we like better than Click
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Click Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Click and related companies with MarketBeat.com's FREE daily email newsletter.
